We are live on
!
Find out more
JBIO
Jade Biosciences
JBIO
JBIO
77 hedge funds and large institutions have $841M invested in Jade Biosciences in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 23 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
32% more capital invested
Capital invested by funds: $639M → $841M (+$203M)
20% more funds holding
Funds holding: 64 → 77 (+13)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
0% more ownership
Funds ownership: 2.91% → 2.92% (+0%)
22% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 23
Holders
77
Holders Change
+13
Holders Change %
+20.31%
% of All Funds
1.11%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
18
Increased
18
Reduced
23
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$9.46M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$8.03M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$4.36M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$3.06M |
| 5 |
SCM
Superstring Capital Management
New York
|
+$2.41M |
Top Sellers
| 1 |
VPC
Vestal Point Capital
New York
|
-$9.05M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.74M |
| 3 |
O
OrbiMed
New York
|
-$4.18M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.27M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$3.24M |
